Year: 2008
Type: letter
Abstract: This study also demonstrated that low baseline serum HBV DNA level in lamivudine-refractory CHB was associated with fewer incidences of subsequent entecavir resistance.This means that an earlier switch to entecavir, while serum HBVDNA levels were relatively low at the time of detection of suboptimal response, could achieve more potent viral suppression and lower rates of resistance for entecavir.Likewise, for those who had suboptimal viral response or viral breakthrough during adefovir therapy, but were not associated with adefovir-resistant mutations, tenofovir still exhibited effective viral suppression.6 However, for patients with adefovir-resistant mutants detected by genotypic analysis, tenofovir might not be sufficient to suppress HBV.Instead, the combination of tenofovir with the nucleoside analog emtricitabine achieved more potent and sustained viral suppression.Consequently, if we continue to use the same class of antiviral therapy, close biochemical, virological, and genotypic surveillance is mandatory for a roadmap to avoid the emergence of drug-resistant mutations.7,8 Although more prospective, randomized, head-to-head studies might be needed to draw this conclusion, to switch or add-on other classes of antiviral therapy seems to be more appropriate if possible.
Source: Hepatology
DOI: 10.1002/hep.22566
Author: Morris Sherman
Institution: Toronto General Hospital
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4248349992
